StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.94−1.06 (-5.05%)

Close on Nov 17, 2026Market cap $5.63BP/E –Yield –

Caris Life Sciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Caris Life Sciences's operating cash flow for the twelve months ending Sep 30, 2026 was $83.89M. For fiscal 2025 it was $83.16M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$83.16M–
FY2024Dec 31, 2024-$245.20M–
FY2023Dec 31, 2023-$276.10M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$22.25M-135.6%
Q2 FY2026Jun 30, 2026$28.48M+290.7%
Q1 FY2026Mar 31, 2026$32.88M–
Q4 FY2025Dec 31, 2025$44.78M–
Q3 FY2025Sep 30, 2025$62.43M–
Q2 FY2025Jun 30, 2025$7.29M–
Q1 FY2025Mar 31, 2025-$31.34M–
Q4 FY2024Dec 31, 2024-$38.92M–
Q3 FY2024Sep 30, 2024-$69.43M–

More Caris Life Sciences figures

See a number that looks wrong?